Search Results

You are looking at 91 - 100 of 2,671 items for :

  • Refine by Access: All x
Clear All
Full access

Christina Signorelli, Claire E. Wakefield, Karen A. Johnston, Joanna E. Fardell, Jordana K McLoone, Mary-Ellen E. Brierley, Maria Schaffer, Elysia Thornton-Benko, Afaf Girgis, W. Hamish Wallace, Richard J. Cohn, and on behalf of the BSU Implementation Group

increasingly recognized as key health professionals in survivorship care delivery, with preliminary evidence suggesting that nurse-led care is safe, acceptable, and feasible. 7 Specialized nurse practitioners have the potential to optimize patient outcomes by

Full access

Luke R.G. Pike, Trevor J. Royce, Amandeep R. Mahal, Daniel W. Kim, William L. Hwang, Brandon A. Mahal, and Nina N. Sanford

higher smoking rates in these populations. 7 , 14 Furthermore, the inferior outcomes observed in patients of lower socioeconomic status (SES) with SCCHN have largely been attributed to a predominance of HPV-negative disease. 7 , 14 However, these

Full access

Quisette P. Janssen, Jacob L. van Dam, Laura R. Prakash, Deesje Doppenberg, Christopher H. Crane, Casper H.J. van Eijck, Susannah G. Ellsworth, William R. Jarnagin, Eileen M. O’Reilly, Alessandro Paniccia, Marsha Reyngold, Marc G. Besselink, Matthew H.G. Katz, Ching-Wei D. Tzeng, Amer H. Zureikat, Bas Groot Koerkamp, Alice C. Wei, and for the Trans-Atlantic Pancreatic Surgery (TAPS) Consortium

pathologic outcomes were collected locally and merged after deidentification. OS was defined from date of tissue diagnosis to date of death, with censoring at the date of last follow-up for patients with no event. The date of final analysis for the cohort was

Full access

Victoria Crossland, Aaron Galaznik, Huamao M. Lin, Dimitrios Tomaras, Shan Ashton Garib, Shuanglian Li, Hui Huang, and Anna Forsythe

and outcome data for the uncommon EGFR exon 20 insertion mutation. Methods: An SLR was performed on August 7, 2018 following the Preferred Reporting Item for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, using the Population, Intervention

Full access

Meagan S. Whisenant, Faith A. Strunk, Debasish Tripathy, and Loretta A. Williams

Background: The use of disease-specific patient-reported outcomes (PROs) is critical for facilitating individualized symptom monitoring and improving cancer patient outcomes. The MD Anderson Symptom Inventory (MDASI) is a PRO measure of symptom

Full access

Nirmala K. Manjappachar, John A. Cuenca, Claudia M. Ramírez, Mike Hernandez, Peyton Martin, Maria P. Reyes, Alba J. Heatter, Cristina Gutierrez, Nisha Rathi, Charles L. Sprung, Kristen J. Price, and Joseph L. Nates

included small cohorts or were spread over long periods, leading to time bias. 5 , 15 , 16 In other studies, severe sepsis and septic shock are reported together. 5 , 14 This article reports on the short-term outcomes and the independent predictors of 28

Full access

Naleen Raj Bhandari, Lisa M. Hess, Dan He, and Patrick Peterson

might not be treated in a way concordant with their test result and treatment guidelines, and a limited number of studies have investigated this in association with eventual survival outcomes. A study based on administrative claims data from 2010 to 2014

Full access

Ronald Chow, Daniel E. Lage, Grant R. Williams, Mina S. Sedrak, Joseph A. Greer, Jennifer S. Temel, and Ryan D. Nipp

that older adults represent less than one-third of cancer clinical trial participants. Moreover, according to a recent meta-analysis of >150 clinical trials, only between 40% and 70% of clinical trials reported on the outcomes of older adult subgroups

Full access

Nivedita Arora, Arjun Gupta, Hong Zhu, Alana Christie, Jeffrey J. Meyer, Saad A. Khan, and Muhammad S. Beg

(RT) considered first-line therapy, and salvage surgery used for resistant or recurrent disease. 8 Race and sex disparities related to access to care and outcomes have been studied for several malignancies, including pancreatic, breast, and lung

Full access

Paul D. Harker-Murray, Lauren Pommert, and Matthew J. Barth

-rituximab era, risk-stratified, response-based, multiagent chemotherapy included higher doses and additional cycles of chemotherapy for patients with higher-stage disease and resulted in cure rates ranging from 79% to 98% ( Table 1 ). Table 1. Outcomes for